Background: Cysteine protease cathepsins are important in extracellular matrix protein degradation, cell apoptosis, and angiogenesis. Mice lacking cathepsins are protected from tumor progression in several animal models, suggesting that the regulation of cathepsin activities controls the growth of various malignant tumors.
Introduction
Cysteine protease cathepsins are secretory lysosomal proteases that mediate both intracellular and extracellular protein degradation. Besides degrading endocytosed unwanted proteins, cathepsins are critical in degrading extracellular matrix collagen, laminin, fibronectin, and elastin, thus playing essential roles in tumor growth [1, 2] . Secreted and cell membrane-bound forms of tumor cathepsins may relate to local cellular behavior in certain cancers [3, 4] . Studies have described increases in cathepsin levels for most invasive cancer types [5] . In cancers, the best-studied cathepsins include cathepsins B (CatB), L (CatL), and S (CatS). In an immunohistological study using samples from human colon cancer patients, CatB was overexpressed and correlated strongly with angiogenesis and regional lymph node metastasis [6] . CatB inhibition in glioblastoma cells via RNA interference (RNAi) resulted in impaired invasion, reduced cell-cell interaction with endothelial cells (EC), disruption of capillary network formation in vitro and in vivo, and inhibition of established glioma tumor growth and invasion in intracranial tumors in vivo [7, 8] . RNAi-mediated CatB inhibition also reduced meningioma cell migration and invasion and led to significant regression of pre-established orthotopic tumors [9] . In an ischemic hindlimb model, CatLdeficient mice showed reduced neovascularization. CatL-deficient EC were less able to support the vascularization at the site of ischemia than were wild-type EC [10] . Transfection of an antiCatL single-chain variable fragment in human melanoma cells inhibited the tumorigenic and metastatic properties completely, therefore producing less angiogenic and smaller tumors [11] . Similar observations were made in a RIP-Tag2 transgenic mouse pancreatic islet cell carcinoma model, in which the rat insulin II promoter (RIP) drove expression of the SV40 large T-antigen (Tag). These tumors also had increased cathepsin expression, which associated with angiogenic vasculature along the invasive front. Reduction in the activity of cathepsins using the pharmacologic inhibitor JPM, or deficiency of CatS, impaired angiogenic switch in progenitor lesions, affecting angiogenesis, tumor growth, vascularity, and invasiveness [12, 13] .
Cystatins are endogenous inhibitors of cysteinyl cathepsins. Cathepsin to cystatin ratio increases in most tumor types, compared to normal tissue, particularly for advanced cancers [14] [15] [16] [17] . Cystatin C, the most important, abundant, and widely expressed cathepsin inhibitor in humans and animals, decreased with concomitant increase of CatB in high-grade gliomas [15] . Benign ovarian cancers had significantly higher cystatin C levels than did malignant tumors [17] ; in prostate cancers, cystatin C levels also decreased at late stages [18] . Nearly 50% of cancers show decreased expression of cystatin C, and perhaps of other cystatins [19] . However, tumor cystatin levels vary widely. In prostate cancers, cystatin C levels remained high at early stages [18] . During colorectal cancer progression, cystatin C remained unchanged between stages, whereas CatB levels remained high at any stage [20] . Serum cystatin C levels are significantly higher in patients with ovarian cancers than in benign ovarian tumors or in healthy women, though serum CatB levels are not different [21] . Similar findings are observed in patients with head and neck squamous-cell carcinoma; serum cystatin C levels in these patients are higher than those from control groups [22] . These observations suggest that the relative ratio of cystatin C to cathepsins in tumor tissues in situ, and not solely the proteases or inhibitors or those in the circulation, are essential in regulating tumor growth.
One approach to directly evaluate the effect of cystatin C on tumor initiation and evolution uses animal models with either increased or decreased expression of this inhibitor. More than 10 years have passed since the generation of the first cystatin Cdeficient mouse to test its function in cancers. When melanoma cells were injected intravenously, cystatin C-deficient lungs showed reduced metastasis, but subcutaneous growth of melanoma cells was not different from that in control mice [23] . In contrast, cystatin C overexpression was associated with decreased glioblastoma cell invasion in vitro and tumor growth in vivo [24] . Such overexpression caused higher apoptosis in vivo for metastatic melanoma cells [25] , and dramatically blocked lung metastasis of human fibrosarcoma cells (,90%) in mice [26] . To date, however, there has been no rigorous experimental examination of how this cathepsin inhibitor participates in tumor growth.
In this study, we introduced cystatin C mutant alleles into the invasive epidermis multistage squamous-cell carcinoma (SCC) mouse model [27] , in which the human keratin-14 promoter/ enhancer drove the expression of human papillomavirus HPV16 early region genes, including the E6/E7 oncogenes, to test whether absence of this dominant cathepsin inhibitor alters the progression of premalignant dysplasia. This established dysplasia to carcinoma model [27] is characterized by temporally and histopathologically reproducible, multi-stage progression of dysplasia by 3 months to SCC by 9 months. Accordingly, it is ideal for evaluation of the effect of cystatin C on cancer progression via the gene knockout approach.
Materials and Methods

Mice and ethics
Cystatin C-deficient (Cstc 2/2 ) mice (C57BL/6/S129 background) [23] were backcrossed to an FVB/n background (Jackson Laboratories, Bar Harbor, ME) for .5 generations. These mice were crossbred with K14-HPV16 transgenic mice [27] (kindly provided by Dr. Lisa Coussen from the University of California, San Francisco), in the same FVB/n genetic background to ensure earlystage (at 3 months) dysplasia. K14-HPV16 transgenic Cstc 2/2 and Cstc +/+ wild-type littermates were sacrificed at 3 months of age.
Chest and ear skin were collected and immediately embedded in compound OCT (optimum cutting temperature) for frozen section preparation (6 mm) or pulverized in liquid nitrogen to prepare tissue extracts for protein (lysed in a pH 5.5 buffer containing 1% Triton X-100, 40 mM sodium acetate, and 1 mM EDTA) or total RNA (lysed in TRIzol reagent; Stratagene, La Jolla, CA) preparation.
To test CatS and cystatin C expression during the progression of hyperplasia and dysplasia, we harvested skin tissues from K14-HPV16 transgenic mice at 1 month, 3 months, and 6 months of age for immunoblot analysis. Due to severe skin premalignant dysplasia from the K14-HPV16 transgenic Cstc 2/2 mice after 3 months of age, we were unable to study mice beyond this time point, for compliance with the humane standard of the Animal Research Committee of Harvard Medical School (approved animal protocol number 03759).
Real-time PCR
Real-time polymerase chain reaction (RT-PCR) was used to determine cathepsin transcript levels, including CatK, CatL, CatS, and CatB, in both chest skin and ear skin from 3-month-old K14-HPV16 transgenic Cstc +/+ and Cstc 2/2 mice. Total cellular RNA was extracted from TRIzol reagent-treated tumor tissue extracts. RNase-free DNase (Ambion, Austin, TX) was used to remove genomic DNA contaminants. Equal amounts of RNA were reversetranscribed, and quantitative PCR was assessed in a single-color RT-PCR detection system (Stratagene). The level of each cathepsin transcript was normalized to that of the b-actin transcript.
Western blot
Protein concentration of each tumor extract in pH 5.5 buffer was determined using Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). An equal amount of protein (30 mg/sample) of each tissue extract preparation was separated on 14% SDS-PAGE, followed by immunoblot analysis with rabbit anti-human cathepsins S, L, and K polyclonal antibodies (1:1000, Calbiochem, San Diego, CA) or rabbit anti-human cystatin C polyclonal antibodies (1:1000; DAKO Corp., Carpinteria, CA), all of which crossreacted with mouse gene products. Goat anti-mouse b-actin polyclonal antibodies (1:5000, Santa Cruz Biotechnology, CA) were used to determine equal protein loading. Densitometry analysis (ImageJ software, Bethesda, MD) was used to determine the relative cathepsin protein levels in skin and ear tissues from K14-HPV16 transgenic Cstc +/+ and Cstc 2/2 mice.
ELISA
To determine systemic cathepsin levels, mouse serum samples from Cstc +/+ and Cstc 2/2 mice were used directly for ELISA. ELISA for CatS, matrix metalloproteinase-9 (MMP-9) (R&D Systems, Inc., Minneapolis, MN), and CatL (Bender MedSystems Inc., Burlingame, CA) were used according to the manufacturers' protocols.
Collagenase and elastase activity assay
A total of 20 mg of chest and ear skin extract from K14-HPV16 transgenic Cstc +/+ and Cstc 2/2 mice was combined to a final volume of 100 ml in EDTA-containing pH 5.5 buffer that was optimized for measuring cysteinyl cathepsin activities, but not MMPs or other neutral serine proteases. Fluorogenic elastin (10 mg/well, DQ elastin, Invitrogen, Carlsbad, CA) or type I collagen (10 mg/well, Calbiochem) were added to a 96-well plate. After adding 3 mM of dithiothreitol (Sigma, St. Louis, MO), the plate was incubated at 37uC for 3 days and read at an excitation of 505 nm and emission of 515 nm. Data were presented as relative fluorescent units.
Immunohistology
Frozen sections (6 mm) prepared from chest and ear skin of the K14-HPV16 transgenic Cstc +/+ and Cstc 2/2 mice were used for conventional histological (hematoxylin and eosin stain) and immunohistological analysis with rabbit anti-human CatS polyclonal antibody (1:170, cross-reacts with mouse CatS) [28] ; rabbit anti-human Ki67 polyclonal antibody (1:750, NovoCastra Laboratories Ltd, Newcastle, UK); rat anti-mouse CD31 (1:150), Mac-3 (1:900), CD4 (1:90), and CD8 (1:100) monoclonal antibodies (Pharmingen, San Diego, CA); rabbit anti-mouse laminin 5 fragment c2 polyclonal antibody (1:250) [29] ; and the TUNEL staining kit (ApopTagH Plus Peroxidase In Situ Apoptosis Kit, Millipore, Billerica, MA). Immunostaining was analyzed using computer-assisted image analysis software (Image-Pro Plus; Media Cybernetics, Bethesda, MD). Data were presented as antigenpositive area (%) or cell number per mm 
Statistical analysis
Due to our relatively small sample sizes and abnormal data point distribution, we used the non-parametric Mann-Whitney U test to examine the statistical significance for all data in this study. All data were presented as mean 6 SEM. P,0.05 was considered statistically significant.
Results
Cystatin C and CatS expression in early hyperplasia and dysplasia stages from K14-HPV16 transgenic mice
As discussed, expression of cathepsins and their inhibitors varies at different stages of tumor growth [22] . To examine whether CatS and cystatin C were also expressed differently during the progression of premalignant dysplasia, we collected chest skin tumor tissues at different stages from K14-HPV16 transgenic mice that were wild-type for cystatin C, including those tumors established at early (3 months) and late (6 months) stages of dysplasia. Immunoblot analysis demonstrated that CatS protein levels plateaued at 3,6 months of age. Normal skins or those from the early stage (e.g., 1 month) had negligible CatS proteins ( Figure 1A ). In contrast, normal skins had high levels of cystatin C protein, which then decreased during premalignant progression, although cystatin C protein did not completely disappear at the 3-month and 6-month progression stages ( Figure 1B ).
Cystatin C deficiency enhanced SCC in K14-HPV16 transgenic mice
To test the effect of cystatin C in SCC, we introduced the K14-HPV16 transgene into Cstc 2/2 and Cstc +/+ littermate control mice by crossbreeding Cstc 2/2 mice [23] with K14-HPV16 transgenic mice [27] . Genomic DNA PCR confirmed the cystatin C genotypes in K14-HPV16 transgenic mice (data not shown). Due to the extent of malignant dysplasia in Cstc 2/2 K14-HPV16 transgenic mice at later time points (after 3 months), for humane purposes, we sacrificed the K14-HPV16 transgenic mice that were Cstc +/+ and Cstc 2/2 at 3 months of age for the remainder of the study. Anti-human cystatin C polyclonal antibody-mediated immunoblot analysis of chest skin tissue extracts from 3-monthold Cstc 2/2 and Cstc +/+ K14-HPV16 transgenic mice confirmed the absence of cystatin C in Cstc 2/2 mice ( Figure 1C ). At the 3-month time point, we observed SCC formation that was clinically more pronounced in skin from the chest (Figure 2A mice as compared with that of the Cstc +/+ mice. These differences were confirmed histologically ( Figure 2F-I) ; whereas back and ear skin from Cstc +/+ mice exhibited dysplasia (nuclear atypia and disordered maturation in epidermal cells, primarily within the lowermost layers), abnormalities were present uniformly throughout a thickened and more hyperkeratotic epidermal layer in the Cstc 2/2 mice, thus qualifying for a designation of SCC in situ. Such SCC formation or dysplasia was absent in Cstc 2/2 or Cstc +/+ mice without the K14-HPV16 transgene (not shown). Therefore, absence of cystatin C enhanced dysplasia to SCC progression in site-matched skin in the K14-HPV16 transgenic mice.
Cystatin C deficiency increased cysteinyl cathepsin expression and activities
Enhanced SCC formation in Cstc 2/2 K14-HPV16 transgenic mice compared with those wild-type for cystatin C suggests the importance of this endogenous cathepsin inhibitor in early tumor progression in vivo. The development of SCC in Cstc 2/2 K14-HPV16 transgenic mice possibly results from altered counterbalance between cystatin C and cathepsins. To test this hypothesis, we prepared total RNA from chest and ear skin and performed RT-PCR. Absence of cystatin C significantly increased the RNA levels of cathepsins L, S, and B in the chest skin and of CatL in the ear skin (Figure 3A/B) . Tumor tissue extract immunoblot analysis using protein samples from the chest skin ( Figure 3C ) or the ear skin ( Figure 3D ) also revealed significantly increased CatS protein in the chest skin extracts ( Figure 3E ) and CatK and CatL proteins in the ear skin extracts (Figure 3F ), as determined by densitometric measurements. In serum from K14-HPV16 transgenic Cstc +/+ and Cstc 2/2 mice, we made similar observations. Serum from the Cstc 2/2 mice had significantly higher levels of both CatS ( Figure 4A ) and CatL ( Figure 4B ) than that from the Cstc +/+ mice, whereas cystatin C deficiency did not significantly affect serum MMP-9 levels ( Figure 4C ). Chest and ear skin immunohistological analysis also revealed increased expression of CatS throughout the epidermis and dermis from Cstc 2/2 mice, compared with those from Cstc +/+ mice ( Figure 5 ).
Absence of cystatin C also enhanced tumor tissue extract cathepsin activities. Upon incubating chest and ear skin extracts in pH 5.5 buffer, which measures only cysteinyl cathepsins [30] , with fluorogenic elastin and collagen, two common matrix protein substrates for cathepsins S, L, K, and B, we found that tumor tissue extracts from both the chest skin and ear skin from Cstc 2/2 mice had significantly higher elastase ( Figure 6A ) and collagenase ( Figure 6B ) activities than those from Cstc +/+ mice. Together, our data demonstrated increased expression and activities of cysteinyl cathepsins in the absence of cystatin C.
Tumor progression often accompanies inflammatory cell infiltrations [31] [32] [33] , including monocytes/macrophages, B and T lymphocytes, NK cells, and neutrophils. These infiltrates often influence the tumor progression directly. For example, in the same K14-HPV16 transgenic mice used in this study, deficiency of CD4 + T cells delays neoplastic progression and lowers tumor incidence [33] . These cells are rich in cathepsin expression and activities [34, 35] . Therefore, increased cysteinyl cathepsin expression and activities in SCC chest and ear skin tissues from Cstc 2/2 mice can be the results of the absence of cystatin C as well as of enhanced inflammatory cell infiltration. To examine this hypothesis, we immunostained both the chest and ear sections from Cstc +/+ and Cstc 2/2 mice for CD4, CD8, and macrophage marker Mac-3. Both chest and ear sections from Cstc 2/2 mice contained significantly higher percentages of CD4-positive areas than did the Cstc +/+ mice ( Figure 7A ). Mac-3-positive areas were also higher in the ear sections, but not in the chest sections, from Cstc 2/2 mice than from Cstc +/+ mice ( Figure 7B ). There were no differences, however, in CD8-positive areas in chest sections (10. Figures 3C-3F , 5, and 6).
Decreased apoptosis and increased cell proliferation in cystatin C-deficient SCC
Tumor cell apoptosis and proliferation are major determinants of growth or progression of cancers [36, 37] . The development of fully evolved in situ SCC in Cstc 2/2 mice, but not in Cstc +/+ mice, suggests that cystatin C deficiency may reduce tumor cell apoptosis and/or increase tumor cell proliferation. To test this possibility, we immunostained both the chest and ear skin tissue frozen sections for TUNEL and for the cell proliferation marker Ki67. Consistent with our hypothesis, tumor tissues (chest and ear skin) from Cstc 2/2 mice had significantly fewer total apoptotic cells than those from Cstc +/+ mice ( Figure 8A ). In Cstc +/+ mouse chest skin, most apoptotic cells were noted in the epidermis and hair sebaceous unit areas. Relatively fewer apoptotic cells appeared in the dermis. However, in Cstc 2/2 mouse chest skin, both the epidermis and sebaceous unit showed noteworthy reduction of apoptotic cells. In contrast, apoptotic cells from the Cstc +/+ mouse ear skin clustered in the dermis, while ear skin from the Cstc 2/2 mice had significantly reduced levels of such apoptotic cells ( Figure 8A ). Significantly more Ki67-positive proliferating cells were identified in the epidermis and sebaceous units from chest skin of the Cstc 2/2 mice than in those from the Cstc +/+ mice ( Figure 8B ). Reduced apoptosis, but increased proliferation in the epidermis and sebaceous unit of Cstc 2/2 mice, thus correlates with progression to SCC in situ. Similar findings were documented in the Cstc 2/2 mouse ear skin. In the epidermis of Cstc 2/2 mouse ear skin, we detected significantly more Ki67-positive cells than in that of the Cstc +/+ mice ( Figure 8B ). In summary, cystatin C deficiency increased cell proliferation but decreased cell apoptosis, thus correlating with progression to SCC in situ in both chest and ear skin, events that likely also developed at other similarly affected sites (e.g., tail and face skin; Figure 2 ).
Cystatin C deficiency led to increased angiogenesis
Cysteinyl cathepsin-mediated angiogenesis is important in cancer progression and tumor growth. We reported that in the pancreatic islet cell carcinoma RIP-Tag2 model, absence of CatS significantly reduced tumor growth [13] . Mechanistically, we demonstrated that CatS mediates extracellular matrix laminin-5 degradation, followed by the production of a pro-angiogenic peptide from laminin-5 proteolysis, named c2 [13, 29] . In CatSdeficient mice, along with reduced tumor growth, we detected significant reduction of this c2 fragment, and concomitantly, greatly impaired angiogenesis [13] . Along with producing the c2 fragment from laminin-5, cysteinyl cathepsins mediate other matrix protein degradation, all of which relate to angiogenesis and tumor growth. In the present study, we conjectured that the absence of cystatin C caused increased cathepsin expression and activities (Figures 3-6 ) and enhanced pro-angiogenic c2 production with promotion of angiogenesis, leading to increased progression to SCC (Figure 2 ). To test this hypothesis, we performed immunohistological analysis of both chest and ear skin from the Cstc +/+ and Cstc 2/2 mice. Consistent with our hypothesis, we detected significantly more c2-positive microvessels in the dermis of both chest and ear skin of Cstc 2/2 mice than in those of Cstc +/+ mice ( Figure 9A ). Along with increased c2 production in Cstc 2/2 mouse chest and ear skin, we observed significant enhancement of CD31-positive microvessels in the skin of these mice, more than twice as many as those from Cstc +/+ mice ( Figure 9B ). Increased angiogenesis in Cstc 2/2 mouse skin may relate to associated progression to SCC.
Discussion
Protease and protease inhibitor counterbalance prove physiologically important and pathologically relevant in human diseases. Increased protease activities, either by increased protease expression or decreased protease inhibitor expression, lead to many common human disorders, such as cardiovascular diseases, metabolic conditions, bone metabolic dysfunction, cancers, and neurological complications. We have previously shown that the absence of cystatin C enhanced atherogenesis in apolipoprotein E-deficient (Apoe 2/2 ) mice [38] . One mechanism of advanced atherogenesis in these Apoe 2/2 mice, increased cathepsin activities, leads to enhanced elastinolysis and collagenolysis, and thus to blood-borne leukocyte accumulation in the neointima. In the present study, although using a different disease model, we found that cystatin C deficiency results in enhanced SCC progression involving a similar mechanism to what we have observed in the cardiovascular system. Absence of this cathepsin inhibitor enhanced cathepsin expression and activity, which altered epidermal cell kinetics and advanced angiogenesis, thereby expediting cancer progression. The function of cathepsins in angiogenesis has been well studied in several disease models [39] . In general, angiogenesis involves extensive extracellular matrix protein degradation and tissue remodeling, which requires protease involvement. But cathepsins can achieve more than just matrix protein degradation. In vitro studies showed that CatB and CatL can liberate collagen IV, laminin, and fibronectin from the basement membrane, generate gelatinolytic fragments, and initiate a ''metastatic cascade,'' thereby promoting angiogenesis and tumor invasion [40] . We recently have shown that CatS degrades the anti-angiogenic peptides arresten, canstatin, and tumstatin, all of which constitute collagen IV degradation products [13, 41] . Further, CatS degrades the natural basement membrane matrix protein laminin-5, and generates pro-angiogenic c2 fragments in vitro [13, 29] . Cysteinyl cathepsin proteolysis of these latent matrix proteins therefore is critical in regulating angiogenesis, and thus in tumor invasion, as we found in the CatS-deficient RIP-Tag2 model. Absence of CatS reduced c2 fragment production, and consequently reduced isletcell carcinoma growth [13] . In the present study, we also detected significantly higher amounts of CatS ( Figure 5 ) and CatS-derived laminin-5 c2 fragments ( Figure 9A ) in chest and ear skin lesions from Cstc 2/2 mice than in those from Cstc +/+ mice. These observations furnish a mechanistic explanation of the increased angiogenesis detected from the chest and ear skin of the Cstc 2/2 mice, compared with those from the Cstc +/+ mice ( Figure 9B ). Cancer cell proliferation and apoptosis closely relate to angiogenesis, and therefore are important in tumor growth. Angiogenesis provides cancer cells with sufficient nutrients for survival and proliferation; reduced angiogenesis thus may cause cancer cell apoptosis or decreased cell proliferation. In return, cancer-cell apoptosis and proliferation can also regulate angiogenesis. Cysteinyl cathepsins can participate importantly in these processes. When co-cultured with human glioblastoma cells, human microvascular EC increased the invasiveness of the glioblastoma cells. On the other hand, glioblastoma cells stimulated microvascular EC proliferation, which CatB-selective inhibitor CA074me can impair [42] . Therefore, increased expression of CatB may enhance EC proliferation in vivo. Although we saw increased expression of several important cathepsins and enhanced cancer cell proliferation in chest and ear skin sections from Cstc 2/2 mice ( Figure 8B ), whether the increase of proliferation associated with angiogenesis remains unknown. Our observation of reduced cancer-cell apoptosis in chest and ear skin from Cstc 2/2 mice ( Figure 8A ) gives some support to this hypothesis.
Although we anticipated enhanced angiogenesis and tumor growth in Cstc 2/2 mice, several aspects of our results remain unexplained, and more studies are required for further understanding of the role of cathepsins in tumorigenesis. First, we frequently have seen that absence of one protease affects the expression of the others -for example, vascular cells from serine protease chymase-deficient [43] or tryptase-deficient (unpublished data) mice express significantly reduced levels of cathepsins. We demonstrated in this study that deficiency of cystatin C increased both RNA and protein levels of most, if not all, tested cathepsins. Second, cathepsins are thought to promote cell apoptosis -for example, CatB cleaves the anti-apoptotic protein Bcl-2 member Bid and creates a pro-apoptotic signal of mitochondrial cytochrome C release [44] . Osteosarcoma cell line U2OS, overex- pressing HPV oncogene E7 and cell cycle regression regulator p21, undergoes apoptosis in a CatB-dependent but caspaseindependent manner. CatB-selective inhibitor CA074me significantly blocked U2OS cell death [45] . Thus, CatB-deficient mice showed reduced cerebral cell losses, whereas a cystatin mutation resulted in increased apoptosis of cerebellar granule cells [46] . A direct role for cathepsins in promoting apoptosis does not explain our finding in this study of increased cathepsin expression and activities, but reduced cancer apoptosis (Figures 3-6, Figure 8A ). One possibility is that increased cathepsin expression and activities in Cstc 2/2 mice enhanced extracellular matrix processing, which may explain why we detected more laminin-5 fragment c2 ( Figure 9A ) and increased angiogenesis ( Figure 9B) . Compared with the chest and ear skin from Cstc 2/2 mice, we found significantly lower numbers of microvessels in the Cstc +/+ mice ( Figure 9B ). Reduced angiogenesis in Cstc +/+ mice may affect nutrient supply, thus increasing cell death and reducing proliferation, although a detailed mechanism of cathepsin function in this SCC cancer model requires further investigation. Third, it is conceivable that angiogenesis is essential for tumorigenesis after angiogenic switch, but less so in early stages. Our data demonstrated that enhanced cathepsin expression expedited malignant transformation, which also can be caused by alterations in growth factor levels, inflammatory cell infiltration (Figure 7) , and associated intracellular signaling. Mechanisms in addition to enhanced angiogenesis may account for more advanced tumorigenesis in Cstc 2/2 mice than in Cstc +/+ mice. In conclusion, this study provides additional in vivo evidence to support direct participation of cysteinyl cathepsins in tumor growth. Based on these findings, we conjecture that the absence of cystatin C also may increase the progression and growth of other types of tumors. Thus, inhibition of cysteinyl cathepsins, either by small molecular inhibitors [47] , antibody therapy [48] , or retrovirus-mediated cathepsin inhibitor delivery [49] , holds potential for the development of novel cancer therapies.
